Shareholders that lost money on Rocket Pharmaceuticals, Inc.(RCKT) Urged to Join Class Action – Contact The Gross Law Firm to Learn More

Core Viewpoint - Rocket Pharmaceuticals, Inc. is facing a class action lawsuit due to allegations of providing misleading statements regarding the safety and clinical trial protocol of its RP-A501 treatment, which resulted in significant stock price decline after the FDA placed a clinical hold on the study following a Serious Adverse Event [3][4]. Group 1: Allegations and Events - The class period for the lawsuit is from September 17, 2024, to May 26, 2025 [3]. - Allegations include that Rocket Pharmaceuticals made overwhelmingly positive statements while concealing material adverse facts about RP-A501's safety, including the risk of Serious Adverse Events (SAEs) [3]. - The company amended the trial protocol to introduce a new immunomodulatory agent without informing shareholders, which led to inflated stock prices [3]. - On May 27, 2025, Rocket announced the FDA's clinical hold on the RP-A501 Phase 2 study after a patient suffered a SAE, ultimately resulting in death [3]. - Following this announcement, Rocket's stock price plummeted from $6.27 per share on May 23, 2025, to $2.33 per share on May 27, 2025, marking a decline of approximately 37% in one trading day [3]. Group 2: Next Steps for Shareholders - Shareholders are encouraged to register for the class action lawsuit by August 11, 2025, to potentially become lead plaintiffs [4]. - Registered shareholders will receive updates through a portfolio monitoring software regarding the case's status [4]. - Participation in the case incurs no cost or obligation for shareholders [4]. Group 3: Law Firm Information - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and fraud [5]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements [5].